International Journal of Nutrition, Pharmacology, Neurological Diseases

REVIEW ARTICLE
Year
: 2022  |  Volume : 12  |  Issue : 3  |  Page : 99--104

The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease: A Perspective on Erythropoietin as a Potential Adjuvant Therapy


Vinothkumar Ganesan1, Mohanraj Nehru3, Geethamalini Shankar2, Venkataraman Prabhu4 
1 Department of Medical Research, Dr V Balaji Dr V Seshiah Diabetes Care and Research Institute, Aminjikarai, Chennai, Tamil Nadu; Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India
2 Department of Mathematics, Sathyabama institute of science and technology, Chennai, Tamil Nadu, India

Correspondence Address:
PhD Venkataraman Prabhu
Associate Professor, Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur – 603203
India

Background: The universal risk to mankind, coronavirus disease 2019 (COVID-19), shares etiological cofactors with a variety of diseases, including anemic chronic kidney disease patients (CKD) with cognitive dysfunction like Alzheimer disease (AD). Understanding the shared links between COVID-19 and CKD, as well as cognitive impairment such as AD, might aid in designing therapeutic ways to combat both. Given the need of developing COVID-19 medicine, the connection and symptoms of CKD with cognitive impairment have been reviewed here, with a focus on memory and learning disturbance. Objective: COVID-19 and CKD with cognitive dysfunction share angiotensin-converting enzyme 2 receptors, and AD indicators include amyloid, tau protein, and glycogen synthase kinase-3β. Anemia in patients with CKD and pulmonary fibrosis is frequently treated with recombinant human erythropoietin (rHuEPO). Through nitric oxide stimulation, neuroprotection, and various organ hypoxias, rHuEPO promotes red blood cells (RBC) growth while also assisting oxygen delivery. Results and Conclusions: In COVID-19, rHuEPO may be advantageous. The common etiological variables and manifestations outlined in this review could aid in the development of therapeutic options for COVID-19 and CKD with cognitive impairment, such as AD, and so help to eliminate the ongoing universal risk.


How to cite this article:
Ganesan V, Nehru M, Shankar G, Prabhu V. The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease: A Perspective on Erythropoietin as a Potential Adjuvant Therapy.Int J Nutr Pharmacol Neurol Dis 2022;12:99-104


How to cite this URL:
Ganesan V, Nehru M, Shankar G, Prabhu V. The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease: A Perspective on Erythropoietin as a Potential Adjuvant Therapy. Int J Nutr Pharmacol Neurol Dis [serial online] 2022 [cited 2022 Dec 8 ];12:99-104
Available from: https://www.ijnpnd.com/article.asp?issn=2231-0738;year=2022;volume=12;issue=3;spage=99;epage=104;aulast=Ganesan;type=0